Gyon Technologies Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gyon Technologies Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,079	Closed	-$1.66M	–	71
2022 Q4	$1.66M	Buy	16,079 +9,653	+150%	+$906K	0.62%	49
2022 Q3	$545K	Sell	6,426 -12,090	-65%	-$1.08M	0.17%	138
2022 Q2	$1.53M	Buy	+18,516	New	+$1.47M	0.43%	75
2022 Q1	–	Sell	-9,917	Closed	-$876K	–	302
2021 Q4	$876K	Buy	+9,917	New	+$818K	0.16%	179
2021 Q1	–	Sell	-3,627	Closed	-$318K	–	409
2020 Q4	$318K	Sell	3,627 -2,594	-42%	-$206K	0.11%	245
2020 Q3	$473K	Buy	+6,221	New	+$629K	0.37%	103
2020 Q1	–	Sell	-20,049	Closed	-$1.7M	–	112
2019 Q4	$1.7M	Buy	+20,049	New	+$1.51M	1.12%	41

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gyon Technologies Capital Management's BMRN Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 16,079 shares — an estimated $1.66M sold.

Gyon Technologies Capital Management first reported a position in BMRN in Q4 2019 and held it in 7 quarters. The position peaked at $1.7M in Q4 2019. 553 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Gyon Technologies Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Gyon Technologies Capital Management sold 16,079 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $1.66M.
Gyon Technologies Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Gyon Technologies Capital Management's BioMarin Pharmaceuticals position peaked at $1.7M in Q4 2019.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.